These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 22776824)

  • 1. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.
    Bailey CJ; Iqbal N; T'joen C; List JF
    Diabetes Obes Metab; 2012 Oct; 14(10):951-9. PubMed ID: 22776824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
    Kaku K; Inoue S; Matsuoka O; Kiyosue A; Azuma H; Hayashi N; Tokudome T; Langkilde AM; Parikh S
    Diabetes Obes Metab; 2013 May; 15(5):432-40. PubMed ID: 23194084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
    Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
    Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
    Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
    Kaku K; Kiyosue A; Inoue S; Ueda N; Tokudome T; Yang J; Langkilde AM
    Diabetes Obes Metab; 2014 Nov; 16(11):1102-10. PubMed ID: 24909293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
    Bailey CJ; Morales Villegas EC; Woo V; Tang W; Ptaszynska A; List JF
    Diabet Med; 2015 Apr; 32(4):531-41. PubMed ID: 25381876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
    Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
    Diabetes Obes Metab; 2011 Oct; 13(10):928-38. PubMed ID: 21672123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
    Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
    Bailey CJ; Gross JL; Pieters A; Bastien A; List JF
    Lancet; 2010 Jun; 375(9733):2223-33. PubMed ID: 20609968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
    Jabbour SA; Frías JP; Ahmed A; Hardy E; Choi J; Sjöström CD; Guja C
    Diabetes Care; 2020 Oct; 43(10):2528-2536. PubMed ID: 32816874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
    Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J
    Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
    Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
    Henry RR; Murray AV; Marmolejo MH; Hennicken D; Ptaszynska A; List JF
    Int J Clin Pract; 2012 May; 66(5):446-56. PubMed ID: 22413962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA; Hardy E; Sugg J; Parikh S;
    Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.